drugset / Trial / NCT03000218

Evaluation of PK and Biomarkers After UDCA Administrations to Subjects Who Are Overweight and Have Liver Problems

NCT03000218

Phase 1 Unknown 30 enrolled Seoul National University Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

A clinical study to evaluate pharmacokinetics, metabolomics and biomarker in subjects who are overweight and have liver problems after ursodeoxycholic acid multiple administration

Timeline

Start
2016-08
Primary completion
2017-06
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Metformin Small molecule 500 mg
Subject Ursodeoxycholic Acid Small molecule 300 mg

Indications